Logimax, 50 mg+5 mg 30 pcs

Logimax is a hypotensive.

Blocks myocardial beta₁-adrenoreceptors (metoprolol) and inhibits calcium ion entry into vascular smooth muscle cells (felodipine).

Pharmacodynamics

Metoprolol reduces the stimulatory effects of catecholamines on the myocardium, cardiac output and BP.

Phelodipine relaxes vascular wall smooth muscle, decreases ROS and potentiates (reciprocally) metoprolol-induced hypotension.

Pharmacokinetics

It is completely absorbed from the gastrointestinal tract. Systemic bioavailability of felodipine is 15%, that of metoprolol – 50%. Binding to plasma proteins in felodipine is 99%. T_1/2 of felodipine is 25 h, metoprolol is 3-5 h. The active substances are metabolized in the liver. 70% of felodipine is excreted as metabolites in the urine, the rest in the feces. Less than 5% of metoprolol is excreted unchanged by the kidneys.

Indications

Hypertension, symptomatic arterial hypertension.

Pharmacological effect

Logimax – antihypertensive.

Blocks beta1-adrenergic receptors of the myocardium (metoprolol) and inhibits the entry of calcium ions into vascular smooth muscle cells (felodipine).

Pharmacodynamics

Metoprolol reduces the stimulating effect of catecholamines on the myocardium, cardiac output and blood pressure.

Felodipine relaxes the smooth muscles of the vascular wall, reduces peripheral vascular resistance and potentiates (mutually) metoprolol-induced hypotension.

Pharmacokinetics

Completely absorbed from the gastrointestinal tract. Systemic bioavailability of felodipine is 15%, metoprolol is 50%. Plasma protein binding of felodipine is 99%. T1/2 of felodipine – 25 hours, metoprolol – 3-5 hours. The active substances are metabolized in the liver. 70% of felodipine is excreted in the form of metabolites in the urine, the rest in the feces. Less than 5% of metoprolol is excreted unchanged by the kidneys.

Active ingredient

Metoprolol, Felodipine

Composition

Active ingredients:

felodipine 5 mg;

metoprolol succinate (as 50 mg metoprolol tartrate) 47.5 mg;

Excipients:

ethylcellulose;

hydroxypropyl methylcellulose;

hydroxypropylcellulose;

lactose anhydrous;

polyoxyl 40 hydrogenated castor oil;

MCC;

paraffin;

polyethylene glycol;

propyl gallate;

silicon dioxide;

sodium aluminum silicate;

sodium stearyl fumarate;

titanium dioxide (E171);

iron oxides (E172).

Pregnancy

Contraindicated during pregnancy.

Breastfeeding should be stopped during treatment.

Contraindications

Hypersensitivity, acute myocardial infarction, unstable angina, severe sinus bradycardia, AV block II-III degree, sick sinus syndrome, severe peripheral circulatory disorders, decompensated heart failure, cardiogenic shock, pregnancy.

Side Effects

From the nervous system and sensory organs: headache, weakness; dizziness, paresthesia, depression, decreased concentration, drowsiness or insomnia; nervousness, anxiety, blurred vision, dry or irritated eyes, conjunctivitis; amnesia, confusion, hallucinations, tinnitus, impaired taste.

From the cardiovascular system and blood (hematopoiesis, hemostasis): facial flushing, bradycardia, palpitations, postural disturbances, cold extremities, peripheral edema; tachycardia, AV block of the first degree, pain in the heart; syncope; gangrene in patients with severe peripheral circulatory disorders, thrombocytopenia.

From the respiratory system: shortness of breath with physical effort; rhinitis.

From the gastrointestinal tract: nausea, abdominal pain, diarrhea or constipation; vomiting, weight loss; dry mouth, changes in liver function tests; hyperplasia of the mucous membrane, increased concentration of liver enzymes.

From the genitourinary system: impotence, sexual dysfunction.

From the musculoskeletal system: myalgia, arthralgia.

From the skin: rash (in the form of urticaria psoriasiform), dystrophic skin lesions; hair loss; photosensitivity.

Allergic reactions: angioedema.

Interaction

Calcium channel blockers such as verapamil potentiate the negative ino- and chronotropic effect.

It enhances the negative ino- and dromotropic effect of antiarrhythmic drugs (quinidine analogues, amiodarone), and the cardiodepressive effect of inhalational anesthetics.

The concentration of metoprolol in plasma is increased by cimetidine, hydralazine, and alcohol, and decreased by rifampicin.

Indomethacin and other prostaglandin synthetase inhibitors weaken the hypotensive effect.

Overdose

Symptoms: hypotension, sinus bradycardia, AV block, heart failure, cardiogenic shock, cardiac arrest, bronchospasm, nausea, vomiting, cyanosis. The first signs appear 20 minutes – 2 hours after administration.

Treatment: induction of vomiting, gastric lavage; symptomatic therapy: in case of severe hypotension, bradycardia or threat of heart failure – beta1-agonist (iv at intervals of 2-5 minutes or infusion); either dopamine (iv) or atropine sulfate to block the vagus nerve; dobutamine, norepinephrine, glucagon (1–10 mg). If necessary, use a cardiac pacemaker. To relieve bronchospasm – intravenous administration of a beta2-agonist.

Storage conditions

At a temperature not exceeding 30 °C

Shelf life

3 years

Manufacturer

AstraZeneca AB, Sweden